AFR: How this PhD-armed investor sees the virus playing out

Antipodes healthcare sector head, Nick Cameron, speaks to The Australian Financial Review about the impacts of coronavirus on markets.

In a time of market crisis, having a PhD in molecular biology on your research team looks like the smartest investment of all.

Antipodes Partners’ healthcare sector head Nick Cameron is not your average investor trying to navigate volatile markets rocked by coronavirus fears, given his CV includes working on the development of a gene therapy for Parkinson’s disease and experience in genetic engineering and viral factors.

The healthcare analyst is watching the spread of the virus closely and says markets should brace for an acceleration in the number of cases as testing ramps up outside China.

Read the full article in The Australian Financial Review

9 March 2020